Kaushik Varadarajan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kaushik Varadarajan has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
- Funda Meric-Bernstam
Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, USA
48 shared publications - Timothy P. DiPeri
Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
44 shared publications - Kurt W. Evans
Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, Texas
34 shared publications - Maria Gabriela Raso
Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, USA
30 shared publications - Ming Zhao
Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, Texas
30 shared publications - Xiaofeng Zheng
Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas
30 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Assessment of Patient-Derived Xenograft Growth and Antitumor Activity: The NCI PDXNet Consensus Recommendations
Supplementary Figure 1 shows (A) spider plots of Log 2 of individual tumor volumes, (B) growth curves representing average Log 2 tumor volumes, (C) spider plots of Log 2 of proportional changes in tumor volume, and (D) growth curves showing Log2 proportional changes in tumor volume of the data shown in Figures 1 and 2.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Assessment of Patient-Derived Xenograft Growth and Antitumor Activity: The NCI PDXNet Consensus Recommendations
Supplementary Figure 1 shows (A) spider plots of Log 2 of individual tumor volumes, (B) growth curves representing average Log 2 tumor volumes, (C) spider plots of Log 2 of proportional changes in tumor volume, and (D) growth curves showing Log2 proportional changes in tumor volume of the data shown in Figures 1 and 2.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Table S2 from Discordance of HER2 Expression and/or Amplification on Repeat Testing
Characteristics of individual discordant HER2 cases
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Discordance of HER2 Expression and/or Amplification on Repeat Testing
Characteristics of individual discordant HER2 cases
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from Discordance of HER2 Expression and/or Amplification on Repeat Testing
Distribution of HER2 IHC and FISH results between local and central testing.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Discordance of HER2 Expression and/or Amplification on Repeat Testing
Distribution of HER2 IHC and FISH results between local and central testing.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Discordance of HER2 Expression and/or Amplification on Repeat Testing
We sought to assess discordance of HER2 status in patients with HER2-amplified/expressing solid tumors who underwent reevaluation of HER2 status. Patients with metastatic solid tumors and HER2 expression by IHC or amplification by FISH/next-generation sequencing on local testing underwent central HER2 IHC/FISH testing with either archival or fresh biopsies and were evaluated for discordance in HER2 status. 70 patients (12 cancer types) underwent central HER2 reevaluation, including 57 (81.4%) with a new biopsy. In 30 patients with HER2 3+ on local IHC, 21 (70.0%) were 3+, 5 (16.7%) were 2+, 2 (6.7%) were 1+, and 2 (6.7%) had 0 HER2 expression on central IHC. In 15 patients whose cancers were 2+ on local IHC, 2 (13.3%) were 3+, 5 (33.3%) were 2+, 7 (46.7%) were 1+, and 1 (6.7%) had 0 HER2 expression on central IHC. HER2 discordance was seen in 16 of 52 (30.8%) of patients with HER2 overexpression/amplification who underwent a new image-guided biopsy. Discordance was observed in 10 (33.3%) of 30 patients who received intervening HER2-targeted therapy and in 6 (23.8%) of 22 patients who did not. In the 8 patients who had central HER2 assessment from the same archival block used for local testing, none were discordant. Discordance of HER2 status is common in patients with tumors previously identified as HER2-expressing, especially in patients with HER2 2+ tumors. Repeat biomarker evaluation may have value when considering HER2-targeted therapies.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Discordance of HER2 Expression and/or Amplification on Repeat Testing
We sought to assess discordance of HER2 status in patients with HER2-amplified/expressing solid tumors who underwent reevaluation of HER2 status. Patients with metastatic solid tumors and HER2 expression by IHC or amplification by FISH/next-generation sequencing on local testing underwent central HER2 IHC/FISH testing with either archival or fresh biopsies and were evaluated for discordance in HER2 status. 70 patients (12 cancer types) underwent central HER2 reevaluation, including 57 (81.4%) with a new biopsy. In 30 patients with HER2 3+ on local IHC, 21 (70.0%) were 3+, 5 (16.7%) were 2+, 2 (6.7%) were 1+, and 2 (6.7%) had 0 HER2 expression on central IHC. In 15 patients whose cancers were 2+ on local IHC, 2 (13.3%) were 3+, 5 (33.3%) were 2+, 7 (46.7%) were 1+, and 1 (6.7%) had 0 HER2 expression on central IHC. HER2 discordance was seen in 16 of 52 (30.8%) of patients with HER2 overexpression/amplification who underwent a new image-guided biopsy. Discordance was observed in 10 (33.3%) of 30 patients who received intervening HER2-targeted therapy and in 6 (23.8%) of 22 patients who did not. In the 8 patients who had central HER2 assessment from the same archival block used for local testing, none were discordant. Discordance of HER2 status is common in patients with tumors previously identified as HER2-expressing, especially in patients with HER2 2+ tumors. Repeat biomarker evaluation may have value when considering HER2-targeted therapies.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations
Supplementary Figure 4. ATM IHC and genomics of PDXs treated with elimusertib 40 mg/kg.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations
Supplementary Figure 4. ATM IHC and genomics of PDXs treated with elimusertib 40 mg/kg.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 8 from Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations
Supplementary Figure 8: PARPi resistant models with response to ATR inhibition.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 8 from Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations
Supplementary Figure 8: PARPi resistant models with response to ATR inhibition.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations
Supplementary Figure 3. Change in body weight of mice bearing 10 different patient derived xenografts treated with elimusertib 40 mg/kg.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations
Supplementary Figure 3. Change in body weight of mice bearing 10 different patient derived xenografts treated with elimusertib 40 mg/kg.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations
Supplementary Figure 5: Tolerability of 40 mg/kg elimusertib
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations
Supplementary Figure 5: Tolerability of 40 mg/kg elimusertib
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 10 from Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations
Supplementary Figure 10: Additional IHC and RPPA results from pharmacodynamic experiments.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 10 from Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations
Supplementary Figure 10: Additional IHC and RPPA results from pharmacodynamic experiments.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations
Supplementary Table 1: Characteristics and treatment histories of PDXs.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations
Supplementary Table 1: Characteristics and treatment histories of PDXs.